{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:45:53Z","timestamp":1790419553827,"version":"4.1.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research Fund for Academician Lin He New Medicine, China","award":["JYHL2018FZD09"],"award-info":[{"award-number":["JYHL2018FZD09"]}]},{"name":"Natural Science Foundation of Shandong Province, China","award":["ZR2017LH029"],"award-info":[{"award-number":["ZR2017LH029"]}]},{"name":"PhD Research Foundation of Affiliated Hospital of Jining Medical University, China","award":["2016-BS-001"],"award-info":[{"award-number":["2016-BS-001"]}]},{"name":"the Supporting Fund for Teachers\u2019Research of Jining Medical University, China","award":["JYFC2018FKJ056"],"award-info":[{"award-number":["JYFC2018FKJ056"]}]},{"name":"Cultivation project of National Natural (SOCIAL) Science Foundation of Jining Medical University, China","award":["JYP201846"],"award-info":[{"award-number":["JYP201846"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Autoimmune hemolytic anemia (AIHA) therapy may be associated with severe complications such as diabetes, hypertension, obesity, osteoporosis, peptic ulcers, infection, and some other diseases. To reduce those effects, we used low-dose rituximab, bortezomib and dexamethasone (LowR-BD regimen) to treat AIHA. The purpose of this study was to evaluate the efficacy and safety of this regimen.<\/jats:p>\n            <jats:p>Seven patients with warm AIHA (wAIHA) admitted from March 2020 to October 2020 were treated with LowR-BD regimen: Rituximab 100\u200amg by intravenous infusion on day 1 combined with bortezomib 1.3\u200amg\/m<jats:sup>2<\/jats:sup> by subcutaneous injection on day 2 plus dexamethasone 20\u200amg by intravenous infusion on days 2, 3. Clinical efficacy and safety were assessed at the regular reexamination of relevant indicators and follow-up.<\/jats:p>\n            <jats:p>After 4 cycles of the LowR-BD regimen, the overall response rate (ORR) was 85.71% with a complete response (CR) of 28.57% and a partial response (PR) of 57.14%. After a median follow-up of 12 (range 7\u201313) months, 5 patients achieved CR and 2 patients had PR status, including 1 patient who did not respond to LowR-BD treatment and reached CR after using methylprednisolone combined with cyclophosphamide. One patient relapsed and achieved PR after retreatment of 2 cycles LowR-BD regimen. The patients tolerated the treatment well and did not complain of apparently adverse reactions except a patient with Sjogren's syndrome and bronchiectasis who developed a severe infection during treatment.<\/jats:p>\n            <jats:p>Low-dose rituximab combined with bortezomib and dexamethasone is effective and relatively safe in patients with wAIHA.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000028679","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T14:03:43Z","timestamp":1643378623000},"page":"e28679","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":21,"title":["Combination of low-dose rituximab, bortezomib and dexamethasone for the treatment of autoimmune hemolytic anemia"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1577-524X","authenticated-orcid":false,"given":"Mingkang","family":"Yao","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine, Jining Medical University, Jining, Shandong Province, China"},{"name":"Department of Hematology, Affiliated Hospital of Jining Medical University, Jining, Shandong Province, China"},{"name":"Institute of Blood and Marrow Transplantation, Jining Medical University, Jining, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Jining Medical University, Jining, Shandong Province, China"},{"name":"Institute of Blood and Marrow Transplantation, Jining Medical University, Jining, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Jining Medical University, Jining, Shandong Province, China"},{"name":"Institute of Blood and Marrow Transplantation, Jining Medical University, Jining, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Jining Medical University, Jining, Shandong Province, China"},{"name":"Institute of Blood and Marrow Transplantation, Jining Medical University, Jining, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Jining Medical University, Jining, Shandong Province, China"},{"name":"Institute of Blood and Marrow Transplantation, Jining Medical University, Jining, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Jining Medical University, Jining, Shandong Province, China"},{"name":"Institute of Blood and Marrow Transplantation, Jining Medical University, Jining, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Jining Medical University, Jining, Shandong Province, China"},{"name":"Institute of Blood and Marrow Transplantation, Jining Medical University, Jining, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Jining Medical University, Jining, Shandong Province, China"},{"name":"Institute of Blood and Marrow Transplantation, Jining Medical University, Jining, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Jining Medical University, Jining, Shandong Province, China"},{"name":"Institute of Blood and Marrow Transplantation, Jining Medical University, Jining, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingtai","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Blood and Marrow Transplantation, Jining Medical University, Jining, Shandong Province, China"},{"name":"Medical Research Center, Affiliated Hospital of Jining Medical University, Jining, Shandong Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Jining Medical University, Jining, Shandong Province, China"},{"name":"Institute of Blood and Marrow Transplantation, Jining Medical University, Jining, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjh.14478","article-title":"The diagnosis and management of primary autoimmune haemolytic anaemia","volume":"176","author":"Hill","year":"2017","journal-title":"Br J Haematol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/1744666X.2018.1521722","article-title":"Current and emerging treatment options for autoimmune hemolytic anemia","volume":"14","author":"Barcellini","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.3390\/jcm9123859","article-title":"New insights in autoimmune hemolytic anemia: from pathogenesis to therapy stage 1","volume":"9","author":"Barcellini","year":"2020","journal-title":"J Clin Med"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.2008.07054.x","article-title":"Rituximab in the treatment of autoimmune haematological disorders","volume":"141","author":"Garvey","year":"2008","journal-title":"Br J Haematol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/bloodadvances.2016001412","article-title":"Bortezomib-based antibody depletion for refractory autoimmune hematological diseases","volume":"1","author":"Ratnasingam","year":"2016","journal-title":"Blood Adv"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-pharmtox-010919-023603","article-title":"Proteasome inhibitor drugs","volume":"60","author":"Fricker","year":"2020","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1763","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis","volume":"14","author":"Neubert","year":"2008","journal-title":"Nat Med"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/rheumatology\/keu393","article-title":"Successful treatment of warm-type haemolytic anaemia with bortezomib in a rituximab-failed systemic lupus erythematosus patient","volume":"54","author":"Wang","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00277-020-03976-w","article-title":"Rapid response to a single-dose rituximab combined with bortezomib in refractory and relapsed warm autoimmune hemolytic anemia","volume":"99","author":"Chen","year":"2020","journal-title":"Ann Hematol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/bjh.16009","article-title":"Bortezomib and dexamethasone, an original approach for treating multi-refractory warm autoimmune haemolytic anaemia","volume":"187","author":"Fadlallah","year":"2019","journal-title":"Br J Haematol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1007\/s00277-020-04135-x","article-title":"Bortezomib and rituximab in multiply relapsed primary warm autoimmune hemolytic anemia","volume":"100","author":"Ames","year":"2021","journal-title":"Ann Hematol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clim.2018.12.010","article-title":"Relapsing Evans syndrome and systemic lupus erythematosus with antiphospholipid syndrome treated with Bortezomib in combination with plasma exchange","volume":"199","author":"Tkachenko","year":"2019","journal-title":"Clin Immunol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.hemonc.2019.05.006","article-title":"Bortezomib for immune thrombocytopenia and autoimmune hemolytic anemia","volume":"13","author":"Muhsen","year":"2020","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood-2011-06-363556","article-title":"Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies","volume":"119","author":"Barcellini","year":"2012","journal-title":"Blood"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/blood-2010-03-259325","article-title":"How I treat autoimmune hemolytic anemias in adults","volume":"116","author":"Lechner","year":"2010","journal-title":"Blood"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.autrev.2014.11.014","article-title":"Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies","volume":"14","author":"Reynaud","year":"2015","journal-title":"Autoimmun Rev"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ajh.24570","article-title":"A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study)","volume":"92","author":"Michel","year":"2017","journal-title":"Am J Hematol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1182\/blood-2018-03-835413","article-title":"Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study","volume":"132","author":"Rossi","year":"2018","journal-title":"Blood"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2009-09-242917","article-title":"Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib","volume":"115","author":"Carson","year":"2010","journal-title":"Blood"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028679","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:27:26Z","timestamp":1746332846000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":19,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028679","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,28]]},"assertion":[{"value":"2021-09-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}